✦ LIBER ✦

5021 Everolimus (RAD001) in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab: a multicenter phase I clinical trial

✍ Scribed by S. Hurvitz; R. O'Regan; M. Campone; C. Manlius; L. Vittori; P. Mukhopadhyay; C. Massacesi; T. Sahmoud; M. Naughton; F. Andre

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

5004 Multicenter phase I clinical trial

✍ F. Cardoso; L. Gianni; G. Jerusalem; A. Fasolo; J. Bergh; V. Dieras; C. Manlius; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

A phase 2 study of everolimus combined w

✍ Hurvitz, Sara A.; Dalenc, Florence; Campone, Mario; OâRegan, Ruth M.; Tjan-Hei 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 327 KB

436 Trastuzumab- (H) and everolimus- (RA

✍ M. Campone; L. Gianni; C. Massacesi; C. Manlius; R. O'Regan; F. Dalenc; L. Vitto 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Phase I trial of oral mTOR inhibitor eve

✍ Guy Jerusalem; Angelica Fasolo; Veronique Dieras; Fatima Cardoso; Jonas Bergh; L 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 326 KB

Weekly docetaxel and trastuzumab for her

✍ S Takao; N Kohno; M Miyashita; I Kokufu; K Wakita 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 319 KB

A Phase I/II Trial of Trastuzumab and Ge

✍ Stacy L. Moulder; Carlos L. Arteaga 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 440 KB